Thiadiazole irak4 inhibitors
A technology of R12 and compounds, applied in the field of novel compounds, can solve problems such as no approved IRAK4 inhibitory drugs
Pending Publication Date: 2021-03-26
GILEAD SCI INC
View PDF8 Cites 0 Cited by
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
[0006] There are currently no approved IRAK4 inhibitors
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View moreImage
Smart Image Click on the blue labels to locate them in the text.
Smart ImageViewing Examples
Examples
Experimental program
Comparison scheme
Effect test
preparation Embodiment 1
[0140] Prepare hard gelatin capsules containing:
[0141]
[0142] The above ingredients are mixed and filled into hard gelatin capsules.
preparation Embodiment 2
[0144] Tablets are prepared using the following ingredients:
[0145]
[0146]
[0147] The ingredients are mixed and compressed to form tablets.
preparation Embodiment 3
[0149] A dry powder inhaler formulation is prepared containing the following components:
[0150] Composition Weight %
[0151] active ingredient 5
[0152] Lactose 95
[0153] Mix the active ingredient with lactose and add the mixture to a dry powder inhaler device.
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More PUM
Login to View More Abstract
A compound of Formula (I), pharmaceutically acceptable salts thereof, deuterated analogs thereof, compositions thereof, and methods of treating disease by using a compound thereof are disclosed.
Description
technical field [0001] The present disclosure relates to novel compounds that are inhibitors of the kinase IRAK4. The present disclosure also relates to methods of preparing compounds and pharmaceutical compositions comprising such compounds. Background technique [0002] Interleukin-1 receptor-associated kinase-4 (IRAK4) is a serine-threonine kinase that acts as a mediator in the interleukin-1 / Toll-like receptor (IL-1 / TLR) signaling cascade. More specifically, IRAK4 is involved in the activation of the adapter protein myeloid differentiation primary response gene 88 (MyD88) signaling cascade and is hypothesized to play a role in inflammatory and fibrotic diseases such as rheumatoid arthritis (RA), inflammatory bowel disease (IBD). ), gout, Lyme disease, arthritis, psoriasis, pelvic inflammatory disease, systemic lupus erythematosus (SLE), Sjogren syndrome, viral myocarditis, acute and chronic tissue damage, nonalcoholic steatohepatitis ( NASH), alcoholic hepatitis and kid...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More Application Information
Patent Timeline
Login to View More Patent Type & Authority Applications(China)
IPC IPC(8): C07D487/04A61P29/00A61K31/5025
CPCC07D487/04A61P29/00Y02A50/30A61K31/5025A61P19/02C07D471/04C07D519/00
Inventor S.阿曼E.M.培根G.布里兹吉斯E.陈C.周J.J.科特尔M.杜克维M.沙特斯基克J.G.泰勒N.E.赖特Z-Y.杨S.M.齐普费尔
Owner GILEAD SCI INC